NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free GALT Stock Alerts $3.29 +0.05 (+1.54%) (As of 03:24 PM ET) Add Compare Share Share Today's Range$3.25▼$3.4150-Day Range$1.93▼$4.2052-Week Range$1.28▼$4.27Volume74,681 shsAverage Volume134,081 shsMarket Capitalization$203.66 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Galectin Therapeutics alerts: Email Address Galectin Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside234.3% Upside$11.00 Price TargetShort InterestBearish6.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$65,248 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.66) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.95 out of 5 starsMedical Sector796th out of 915 stocksPharmaceutical Preparations Industry381st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.47% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 18.7, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 21.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GALT. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for GALT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have sold 354.37% more of their company's stock than they have bought. Specifically, they have bought $14,360.00 in company stock and sold $65,248.00 in company stock.Percentage Held by Insiders52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.66) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Galectin Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. About Galectin Therapeutics Stock (NASDAQ:GALT)Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More GALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GALT Stock News HeadlinesApril 26, 2024 | insidertrades.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells 21,323 Shares of StockApril 30, 2024 | money.usnews.comGalectin Therapeutics IncMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.April 20, 2024 | morningstar.comGalectin Therapeutics Inc GALTApril 9, 2024 | markets.businessinsider.comGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of BelapectinApril 9, 2024 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisApril 5, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023April 3, 2024 | benzinga.comGalectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, PredictionsMay 9, 2024 | InvestorPlace (Ad)1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.April 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial StabilityMarch 29, 2024 | finanznachrichten.deGalectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 29, 2024 | msn.comWhat retail stores are open Easter 2024? Details on Walmart, Target, Macy's, Kohl's, moreMarch 29, 2024 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business DevelopmentsMarch 29, 2024 | globenewswire.comGalectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | seekingalpha.comGalectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection PointMarch 14, 2024 | msn.comMadrigal granted FDA approval for NASH therapyMarch 13, 2024 | msn.comLiver drug developers outperform as U.S. awaits first NASH drugMarch 12, 2024 | globenewswire.comGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentFebruary 29, 2024 | seekingalpha.comGALT Galectin Therapeutics Inc.February 21, 2024 | finance.yahoo.comRetail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%November 14, 2023 | markets.businessinsider.comArce’s Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial OutlookNovember 13, 2023 | msn.comGalectin Therapeutics GAAP EPS of -$0.24November 13, 2023 | benzinga.comGalectin Therapeutics: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comUPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023November 3, 2023 | finance.yahoo.comGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDSee More Headlines Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/09/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GALT CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees28Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+239.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-197.39% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.01) per share Price / Book-3.21Miscellaneous Outstanding Shares61,904,000Free Float29,281,000Market Cap$200.57 million OptionableOptionable Beta0.72 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joel Lewis (Age 54)President, CEO & Director Comp: $907.72kMr. Jack W. Callicutt CPA (Age 57)CFO, Treasurer & Corporate Secretary Comp: $521.47kDr. Pol F. Boudes M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $730.33kRobert TrittGeneral CounselMr. Jeff KatstraHead of CMC & Pharmaceutical DevelopmentMs. Beth KnowlesExecutive Assistant & Officer ManagerMore ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLTrevi TherapeuticsNASDAQ:TRVIOmerosNASDAQ:OMERGeneration BioNASDAQ:GBIOOvid TherapeuticsNASDAQ:OVIDView All CompetitorsInsiders & InstitutionsWealthspire Advisors LLCBought 214,512 shares on 5/7/2024Ownership: 0.644%Geneos Wealth Management Inc.Sold 3,800 shares on 5/4/2024Ownership: 0.660%Richard A Jr. ZordaniBought 1,000 shares on 4/30/2024Total: $3,520.00 ($3.52/share)Joel LewisBought 1,000 shares on 4/24/2024Total: $3,390.00 ($3.39/share)James C CzirrSold 21,323 sharesTotal: $65,248.38 ($3.06/share)View All Insider TransactionsView All Institutional Transactions GALT Stock Analysis - Frequently Asked Questions Should I buy or sell Galectin Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GALT shares. View GALT analyst ratings or view top-rated stocks. What is Galectin Therapeutics' stock price target for 2024? 1 brokerages have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 234.3% from the stock's current price. View analysts price targets for GALT or view top-rated stocks among Wall Street analysts. How have GALT shares performed in 2024? Galectin Therapeutics' stock was trading at $1.66 at the start of the year. Since then, GALT shares have increased by 98.2% and is now trading at $3.29. View the best growth stocks for 2024 here. Are investors shorting Galectin Therapeutics? Galectin Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,740,000 shares, an increase of 21.8% from the March 31st total of 2,250,000 shares. Based on an average trading volume of 146,900 shares, the days-to-cover ratio is presently 18.7 days. Approximately 6.5% of the shares of the company are sold short. View Galectin Therapeutics' Short Interest. When is Galectin Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GALT earnings forecast. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings data on Friday, March, 29th. The company reported ($0.16) earnings per share for the quarter. What ETF holds Galectin Therapeutics' stock? Horizon Kinetics Medical ETF holds 53,742 shares of GALT stock, representing 1.09% of its portfolio. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU). Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Geneos Wealth Management Inc. (0.66%), Wealthspire Advisors LLC (0.64%) and Retirement Guys Formula LLC (0.05%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GALT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
